223 related articles for article (PubMed ID: 19939189)
1. Patented PDE10A inhibitors: novel compounds since 2007.
Kehler J; Kilburn JP
Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
Kehler J
Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
[TBL] [Abstract][Full Text] [Related]
3. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
4. P2X purinergic receptor ligands: recently patented compounds.
Gunosewoyo H; Kassiou M
Expert Opin Ther Pat; 2010 May; 20(5):625-46. PubMed ID: 20205618
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
8. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
11. New patented histone deacetylase inhibitors.
Wang H; Dymock BW
Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
[TBL] [Abstract][Full Text] [Related]
14. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
15. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
16. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
[TBL] [Abstract][Full Text] [Related]
17. Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
Al-Nema M; Gaurav A; Akowuah G
Comput Biol Chem; 2018 Dec; 77():52-63. PubMed ID: 30240986
[TBL] [Abstract][Full Text] [Related]
18. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
[TBL] [Abstract][Full Text] [Related]
19. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
20. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker.
Dedeurwaerdere S; Wintmolders C; Vanhoof G; Langlois X
J Pharmacol Exp Ther; 2011 Oct; 339(1):210-7. PubMed ID: 21742809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
